Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Moderate to Severe COPD (Stage II or Stage III) according to the GOLD 2010 guideline~* Current or ex-smokers who have a smoking history of at least 10 pack years~* Qualifying FEV1 at Visit 2 (day -7)~Exclusion Criteria:~* Patients with a history of asthma or a history of high blood eosinophil count (\>600/mm³)~* Patients with concomitant pulmonary disease~* Patients with lung lobectomy or lung volume reduction or lung transplantation~* Patients with α-1 antitrypsin deficiency~* Patients who have had live attenuated vaccinations within 30 days prior to screening visit or during run-in period~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 + Fluticasone/Salmeterol (Flu/Sal) (Type: EXPERIMENTAL): NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
- Tiotropium + Flu/Sal (Type: ACTIVE_COMPARATOR): Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
- Flu/Sal (Type: PLACEBO_COMPARATOR): Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).